CDP choline production promoter

Linden extract promotes CDP choline production in keratinocytes, addressing the gap in wound healing effects by enhancing keratinocyte migration and skin barrier function through increased expression of tight junction proteins.

JP7579469B1Active Publication Date: 2024-11-07SHISEIDO CO LTD
View PDF 21 Cites 0 Cited by

Patent Information

Application Number
JP2024013256
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-01-31
Publication Date
2024-11-07
Estimated Expiration
2044-01-31

AI Technical Summary

Technical Problem

There is a lack of understanding on the effects of linden extract on epidermal cells, particularly in promoting wound healing, and its role in enhancing CDP choline production for epidermal regeneration.

Method used

The use of linden extract to promote CDP choline production in keratinocytes, which increases the expression of tight junction-related proteins and enhances keratinocyte migration, thereby facilitating wound healing and improving skin barrier function.

Benefits of technology

Linden extract stimulates CDP choline production, leading to enhanced keratinocyte migration, wound healing, and strengthened skin barrier function by increasing the expression of proteins like claudin, occludin, and ZO-1.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007579469000001_ABST
    Figure 0007579469000001_ABST
Patent Text Reader

Abstract

The purpose is to obtain components that promote epidermal regeneration. The present inventors have found that CDP choline exerts effects such as promoting epidermal regeneration, promoting keratinocyte migration, wound healing, enhancing cell membranes, and improving skin barrier function, and provide a CDP choline production promoter, or an epidermal regeneration promoter, a keratinocyte migration promoter, a wound healing promoter, a keratinocyte cell membrane enhancer, or a skin barrier function promoter that contains CDP choline. In addition, the present inventors provide linden extract as a CDP choline production promoter.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] This invention relates to the technical field of promoting the production of CDP-choline. By promoting the production of CDP-choline, epidermal regeneration can be promoted, and effects such as promotion of keratinocyte migration, wound healing, strengthening of cell membranes, and improvement of skin barrier function can be exhibited. [Background technology]

[0002] CDP choline is a substance in which choline is bound to cytidine diphosphate (CDP), a nucleotide, via a phosphate ester bond. CDP choline is one of the intermediates in the biosynthetic pathway of phosphatidylcholine and also one of the intermediates in the biosynthesis of sphingomyelin. CDP choline has been reported to have an effect of improving cognitive function and to have a neuroprotective effect (Patent Document 1: JP 2023-011800 A, Patent Document 2: JP 2022-107631 A), and is sold as a medical drug in Japan and as a supplement overseas. In addition, it has been reported that CDP choline acts on vascular endothelial cells and affects the expression of ZO-1 and occludin, which are tight junction factors (Non-Patent Document 1: PLoS One. 2013).

[0003] Linden extract obtained from the western linden tree is known to have various effects such as elastase activity inhibition, hyaluronidase activity inhibition, collagenase activity inhibition, SOD-like action, DPPH radical scavenging action, PGE2 production inhibition, MMP1 activity inhibition, AGEs production inhibition, and estrogen-like action. These activities mainly act on the dermis layer, and it is used in cosmetics for various purposes such as improving sagging, promoting collagen production, and whitening, as well as in foods such as herbal tea and supplements. However, there have been few reports on its effect on epidermal cells, and its effect on wound healing was unknown. [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Patent Publication No. 2023-011800 [Patent Document 2] JP 2022-107631 A [Non-patent literature]

[0005] [Non-Patent Document 1] Ma X, et al. Plops One. 2013. https: / / doi.org / 10.1371 / journal.pone.0082604 Summary of the Invention [Problem to be solved by the invention]

[0006] The purpose is to obtain components that promote epidermal regeneration. [Means for solving the problem]

[0007] The present inventors found that the addition of CDP-choline to cultured keratinocytes increases the expression of tight junction-associated proteins and promotes the migration of keratinocytes in scratch assays. Thus, focusing on the epidermal regeneration effect of CDP-choline, they screened for ingredients that act on the epidermis by promoting the production of CDP-choline in the body, and surprisingly found that Linden Extract increases the production of CDP-choline in keratinocytes, leading to the present invention. Thus, the present invention relates to: [1] Contains linden extract, a CDP choline production enhancer. [2] The CDP choline production promoter described in Item 1, which promotes CDP choline production in keratinocytes. [3] An epidermal regeneration promoter comprising the CDP choline production promoter described in item 1 or CDP choline. [4] A keratinocyte migration promoter comprising the CDP-choline production promoter described in item 1 or CDP-choline. [5] A wound healing promoter comprising the CDP-choline production promoter described in item 1 or CDP-choline. [6] A keratinocyte cell membrane enhancer comprising the CDP-choline production promoter described in item 1 or CDP-choline. [7] A skin barrier function promoter comprising the CDP choline production promoter described in item 1 or CDP choline. [8] A composition for transdermal or oral administration containing the CDP choline production promoter or CDP choline described in item 1. [9] The composition according to item 8, which is a cosmetic composition or a pharmaceutical composition.

[10] A food comprising the CDP choline production promoter described in item 1.

[11] A wound healing method comprising applying a CDP-choline production promoter containing linden extract to a wound area of ​​a subject having a wound.

[12] A cosmetic method comprising applying a CDP choline production promoter containing linden extract to a subject having rough skin.

[13] Linden extract for use in wound healing.

[14] The linden extract according to item 13, which promotes the production of CDP-choline, thereby healing wounds.

[15] The linden extract described in Item 14 promotes the production of CDP-choline, thereby promoting epidermal regeneration, promoting keratinocyte migration, strengthening the cell membrane of keratinocytes, and improving skin barrier function.

[16] CDP choline for use in wound healing.

[17] The CDP choline according to Item 16, which heals wounds through promotion of epidermal regeneration, promotion of keratinocyte migration, strengthening of keratinocyte cell membranes, or improvement of skin barrier function.

[18] Use of linden extract for the manufacture of a CDP choline production promoter.

[19] Use of linden extract or CDP choline for the manufacture of an epidermal regeneration promoter, a keratinocyte migration promoter, or a wound healing promoter. Effect of the Invention

[0008] Linden extract promotes the production of CDP choline, which contributes to epidermal regeneration, promotion of keratinocyte migration, wound healing, strengthening of cell membranes, and improvement of skin barrier function. [Brief description of the drawings]

[0009] [Figure 1] Figure 1 shows the results of metabolomic analysis of keratinocytes cultured with the addition of linden extract. Compared to the control group (without linden extract added), metabolites that were produced in increased amounts are written in black, and metabolites that were produced in decreased amounts are written in red (A). The vertical axis shows the negative common logarithm of the P-value of the significant difference test by T-test between the production amounts of the linden extract added group and the control group, and the horizontal axis shows the base 2 logarithm of the ratio of change in production amount of the linden extract added group to the control group. Focusing on CDP choline, the change in production amount is shown in a graph (B). The vertical axis shows the relative area value of CDP choline against the internal standard substance. [Diagram 2] FIG. 2 shows changes in the expression of claudin (A), occludin (B), and ZO-1 (C) when keratinocytes were cultured with the addition of CDP-choline (0.05% and 0.1%). [Diagram 3] Figure 3 shows fluorescent immunostaining photographs (A) showing the localization of occludin protein in keratinocytes cultured under hypoxic conditions (1% oxygen) without (Control) or with (citicoline) CDP-choline added, and a graph (B) showing the results of quantification from the fluorescent immunostaining photographs. [Figure 4] FIG. 4 shows a photograph (A) of a scratch assay of keratinocytes cultured under hypoxic conditions (1% oxygen) without (Control) or with (citicoline) CDP-choline added, and a graph (B) showing changes in cell density. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0010] The present invention relates to a CDP-choline production promoter comprising a linden extract. When the production of CDP-choline is promoted in keratinocytes, it contributes to epidermal regeneration, promotion of keratinocyte migration, wound healing, strengthening of cell membranes, and improvement of skin barrier function.

[0011] CDP choline has the following formula: [ka] It is a compound represented by the formula (I) and is also called citicoline. CDP choline is produced in any cell and contributes to the production of phosphatidylcholine and sphingomyelin. Phosphatidylcholine is a main component of cell membranes, and in nerve cells, it is the source of acetylcholine, a neurotransmitter. By increasing the production amount of CDP choline, the amount of phosphatidylcholine and / or sphingomyelin in the cell membrane increases. Sphingomyelin is considered to be involved in the formation of raft regions, and the stability of lipid bilayer membranes increases by increasing these phospholipids. Thus, the present invention may relate to a cell membrane enhancer containing CDP choline.

[0012] The CDP-choline production promoter is a component that promotes the production of CDP-choline in any cell, particularly keratinocytes, when applied. The promotion of CDP-choline production in keratinocytes contributes to epidermal regeneration, promotion of keratinocyte migration, wound healing, strengthening of cell membranes, and improvement of skin barrier function.

[0013] When the skin is wounded, bleeding occurs first. Over time, the blood coagulates and a scab forms. Inside the scab, keratinocytes around the wound proliferate and migrate to seal the wound, while differentiation into the stratum corneum occurs, forming tight junctions as they differentiate. The formation of tight junctions improves the skin barrier function and regenerates the epidermis.

[0014] Keratinocytes usually divide repeatedly in the basal layer, and when the divided cells migrate to the surface layer, they differentiate to form the spinous layer, granular layer, and stratum corneum. On the other hand, when an injury occurs to the skin, keratinocytes around the injured area and their precursor cells, epidermal stem cells, begin to migrate to the injured area. Migration is induced, for example, by a hypoxic state, and migration is promoted by internal keratinocytes that are blocked from the outside air by a scab or the like. The migration ability of keratinocytes can be measured by performing a scratch assay in cultured cells. The scratch assay is a method in which cells in a part of the surface of a dish cultured to confluence are scraped off, and then the migration ability is determined based on the cells that have migrated to the part after the cells have been scraped off. It was shown that the culture to which CDP-choline was added had a high migration ability (FIGS. 4A and B). Thus, the present invention may relate to a keratinocyte migration promoter, wound healing promoter, or epidermal regeneration promoter in keratinocytes, which contains CDP-choline.

[0015] Tight junctions are formed between cells in the granular layer of the stratum corneum, and the formation of tight junctions exerts the skin barrier function. This prevents the loss of components and moisture inside the skin, and prevents the invasion of allergens and pathogens from the outside of the skin. Claudin, occludin, ZO family proteins (ZO-1 to ZO-3), etc. are known as tight junction factors involved in tight junctions. By increasing the expression of these proteins, the tight junctions become stronger, and the skin barrier function is enhanced. In addition, tight junctions are formed not only in keratinocytes, but also in epithelial cell systems, such as intestinal epithelial cells and vascular endothelial cells. It is known that CDP-choline enhances the expression of tight junction factors in vascular endothelial cells under hypoxia (Non-Patent Document 1). The present inventors have shown that CDP-choline enhances the expression of tight junction factors in keratinocytes under hypoxic conditions (FIGS. 2A to 2C), and have also shown that CDP-choline enhances the expression of occludin localized in the cell membrane in keratinocytes cultured under hypoxic conditions (FIGS. 3A and 3B). Thus, the present invention can be said to be a promoter of tight junction formation in keratinocytes or a skin barrier function enhancer, which contains CDP-choline.

[0016] Linden extract is an extract extracted from a plant belonging to the genus Tillia in the family Tilia. Examples of plants belonging to the genus Tillia in the family Tilia include T. americana L., T. platyphyllos Scop., T. cordata Mill., and hybrids thereof, such as Tilia × europaea. Linden extract is also called linden extract or tilia extract. These plant extracts can be obtained by a general method for producing plant extracts from at least one part of the plant body, particularly buds, leaves, flowers, branches, trunks, roots, fruits, and seeds. As an example, the extract can be obtained by immersing or refluxing the flowers or buds as they are or by drying them with an extraction solvent at room temperature or at high temperature, followed by filtering and concentrating. As the extraction solvent, any solvent that is usually used for extraction can be used. For example, aqueous solvents such as water, physiological saline, phosphate buffer, borate buffer, or organic solvents such as alcohols such as ethanol, propylene glycol, 1,3-butylene glycol, glycerin, water-containing alcohols, chloroform, dichloroethane, carbon tetrachloride, acetone, ethyl acetate, hexane, etc. can be used alone or in combination. Preferably, a mixed solvent of water and alcohol, such as 1,3-butylene glycol, is used as the solvent. The extract obtained by extraction with the above solvent can be used as it is, or the extract concentrated by, for example, freeze-drying, and if necessary, it can be used after removing impurities using an adsorption method, for example, an ion exchange resin, or after adsorption on a column of porous polymer (e.g., Amberlite XAD-2), eluted with a desired solvent, and further concentrated. Commercially available linden extracts can also be used. More specifically, it can be prepared by extraction with water, alcohol, or a mixture thereof. As the alcohol, ethanol, propylene glycol, or butylene glycol can be used. More preferably, extraction can be performed with a mixture of water and alcohol in any ratio, for example, a 10:90 to 90:10 mixture, preferably a 30:70 to 70:30 mixture, and further preferably a 50:50 mixture.More preferably, a mixture of water and 1,3-butylene glycol is used. Linden extract is blended in the cosmetic composition at a concentration of 0.005% to 0.1%, more preferably 0.01% to 0.05%.

[0017] Linden extract can promote the production of CDP-choline in cultured keratinocytes (FIGS. 1A and 1B), and thus Linden extract can be used as a CDP-choline production promoter. Furthermore, CDP-choline can promote the expression of claudin, occludin, and ZO-1 in keratinocytes (FIGS. 2A-C, 3A and 3B), and further promotes keratinocyte migration in a scratch assay (FIGS. 4A and 4B). Thus, Linden extract can also exert an effect via the production of CDP-choline. Thus, the present invention may relate to an epidermal regeneration promoter, a keratinocyte migration promoter, a wound healing promoter, a cell membrane enhancer, and a skin barrier function improver, each of which contains Linden extract.

[0018] The CDP choline production promoter, epidermal regeneration promoter, keratinocyte migration promoter, wound healing promoter, cell membrane enhancer, and skin barrier function improver of the present invention may be incorporated into cosmetics, pharmaceuticals, or quasi-drugs, and may also be incorporated into foods, such as dietary supplements such as supplements, and functional foods. Foods can also be called food compositions, and can be administered to subjects suffering from rough skin, wounds, scratches, and reduced skin barrier function. These drugs may be administered orally or parenterally, for example, transdermally. When administered transdermally, they can be formulated into a skin topical agent. The skin topical agent is not particularly limited as long as it can be applied to the skin, and any formulation such as a solution, emulsion, solid, semi-solid, powder, powder dispersion, water-oil two-layer separation, water-oil-powder three-layer separation, ointment, gel, aerosol, mousse, and stick can be applied. When formulated into a skin external preparation, a base and excipients, such as a preservative, an emulsifier, and a pH adjuster, that are generally used in skin external preparations may be used. In addition, the composition may be formulated into a patch to cover a wound. When incorporated into cosmetics, the composition may be incorporated into face or body cosmetics such as lotions, milky lotions, beauty essences, creams, lotions, packs, essences, gels, and other makeup cosmetics, such as foundations, makeup bases, and concealers, and even bath additives. By using cosmetics, medicines, and quasi-drugs containing the components of the present invention, at least one action selected from the group consisting of promoting epidermal regeneration, promoting keratinocyte migration, promoting wound healing, strengthening cell membranes, and improving skin barrier function can be achieved through the promotion of CDP-choline production in cells, particularly keratinocytes.

[0019] The CDP choline production promoter, epidermal regeneration promoter, keratinocyte migration promoter, wound healing promoter, cell membrane enhancer, and skin barrier function improver of the present invention can be arbitrarily selected in concentration from the viewpoint of exerting the desired effect, for example, improving skin barrier function and promoting skin regeneration ability. From the viewpoint of blending as a skin external preparation, the extract of the present invention can be blended at 0.0005% to 0.5%. From the viewpoint of fully exerting the effect, it can be blended preferably at 0.001% or more, and more preferably at 0.005% or more. From the viewpoint of avoiding a strong odor, it can be blended preferably at 0.1% or less, and more preferably at 0.05% or less.

[0020] In yet another aspect of the present invention, the present invention may relate to a method for promoting epidermal regeneration, promoting keratinocyte migration, promoting wound healing, enhancing cell membrane, and improving skin barrier function through promoting the production of CDP-choline. More specifically, the method of the present invention also relates to a method comprising a step of applying a composition containing CDP-choline according to the present invention or a composition containing linden extract to the skin of a subject. Such a method may be a therapeutic method or a non-therapeutic cosmetic method. Such a subject is a subject who desires to promote epidermal regeneration, promote keratinocyte migration, promote wound healing, enhance cell membrane, and improve skin barrier function, and may be administered to a subject suffering from rough skin, skin inflammation, or scratches, for example.

[0021] All documents mentioned in this specification are incorporated herein by reference in their entirety. The following examples of the present invention are for illustrative purposes only and do not limit the technical scope of the present invention. The technical scope of the present invention is limited only by the claims. The present invention can be modified, for example, by adding, deleting, and replacing the constituent elements of the present invention, without departing from the spirit of the present invention. EXAMPLES

[0022] Example 1: Metabolomic analysis A culture of human keratinocytes (Kurabo) seeded in a growth medium for human epithelial cells (CELLnTEC) was added with 0.1% linden extract (Koei Kogyo Co., Ltd.) and cultured for 6 hours. After the culture, the medium was removed, a methanol solution was added and stirred, and Milli-Q water was added and stirred, followed by centrifugation (2,300 x g, 4°C, 5 minutes). After ultrafiltration using an ultrafiltration tube (Ultrafree MC PLHCC, HMT, centrifugal filter unit 5 kDa), the filtrate was dried and dissolved in Milli-Q water again for measurement. 1.26 x 10 per sample 6 Metabolomic measurements were performed using N=5 cells.

[0023] Metabolite detection Cationic and anionic metabolites were comprehensively detected by a CE-MS system combining capillary electrophoresis (Agilent CE system) and a mass spectrometer (MS). Peaks with a signal / noise (S / N) ratio of 3 or more were automatically extracted from the detected peaks using automatic integration software, and mass / charge ratios (m / z), peak area values, and migration time (MT) were obtained. Peaks with a signal / noise (S / N) ratio of 3 or more were automatically extracted, and mass / charge ratios (m / z), peak area values, and migration time (MT) were obtained. Based on the m / z and MT values, the metabolites were identified by matching and searching with all substances registered in the HMT metabolite library. The results are shown in Figure 1 (A). Components whose production increased with the addition of linden extract are written in black, and components whose production decreased are written in gray. Focusing on CDP-choline, the change in production is shown (Figure 1 (B)).

[0024] Example 2: Effect of Addition of CDP-choline After seeding in a human epithelial cell growth medium (CELLnTEC), human keratinocytes (Kurabo) cultured in a human epithelial cell differentiation medium (CELLnTEC) were added with CDP-choline (Sigma-Aldrich, final concentration 0.1 mM) and cultured at 1% oxygen concentration for 24 hours. Total RNA was extracted and cDNA was prepared using AffinityScript QPCR cDNA Synthesis Kit (Agilent Technologies). qPCR was performed using LightCycler (registered trademark) FastStart DNA MasterPLUS SYBR Green I and LightCycler (Roche Molecular Systems, Inc., Pleasanton). Gene expression of claudin, occludin, and ZO-1 was measured using the following primers and quantified by the ΔCt method using GAPDH as a standard according to the attached instructions. The results are shown in Figure 2. [Table 1]

[0025] Cell immunostaining After seeding in a human epithelial cell medium (CELLnTEC), human keratinocytes (Kurabo) cultured in a human epithelial cell differentiation medium (CELLnTEC) were added with CDP choline (final concentration 0.1 mM) and cultured at 1% oxygen concentration for 24 hours, then fixed with methanol. After blocking with 4% skim milk, the cells were reacted with anti-occludin monoclonal antibody (Invitrogen) overnight at 4°C, and finally reacted with Alexa Fluor 594-labeled anti-mouse IgG antibody (Invitrogen) and detected with a confocal microscope LSM880 (Leica). The fluorescence intensity of the obtained images was quantified using ImageJ image analysis software. The results are shown in Figure 3 (A) and (B).

[0026] Scratch assay The experiment was carried out according to the instructions of the Incucyte® 96-Well Scratch Wound Cell Migration and Invasion Assays module (Sartorius). After culturing human keratinocytes on an Incucyte® Imagelock 96-Well Plate (Sartorius) until they became confluent, cells were scraped off at a certain width using the Incucyte® 96-Well Woundmaker Tool (Sartorius) to create grooves on the wells, and CDP-choline (final concentration 0.1 mM) was added and the culture was carried out at 1% oxygen concentration for 36 hours. The state in which the cell-free areas on the wells were filled was analyzed using the Incucyte Live Cell Analysis System. The results are shown in Figure 4(A). The cell density at the scratch site was calculated (Figure 4(B)).

Claims

1. Contains linden extract, a CDP choline production promoter.

2. The CDP choline production promoter of claim 1 , which promotes CDP choline production in keratinocytes.

Citation Information

Patent Citations

  • Inflammation-diminishing and repairing linden cream and preparation method thereof

    CN115844746A

  • Production of protein degradable by protease derived from host cell

    JP1996023995A

  • Preparation for external use for skin

    JP1997301880A

  • Oral administrational preparation for inhibiting intercellular adhesion

    JP1999116493A

  • Acne medicine originated from natural product

    JP2001097842A